ALPHARETTA, Ga.--(BUSINESS WIRE)--Cartiva, Inc., a developer of innovative solutions for the treatment of cartilage damage and osteoarthritis, today announced the publication of a peer-reviewed article entitled “5 to 8 years follow-up of knee chondral defects treated by PVA-H hydrogel implants.” The study, which was published in the December issue of European Review for Medical and Pharmacological Sciences, demonstrated the effectiveness of Cartiva Synthetic Cartilage Implant (SCI) for up to eight years in patients with focal cartilage injuries in the knee. Cartiva SCI is a proprietary polyvinyl alcohol (PVA) hydrogel that was designed to mimic natural cartilage.
Help employers find you! Check out all the jobs and post your resume.